Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation (Q69741866)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2787694%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

title

Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2787694%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

S D Voss

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2787694%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

J A Hank

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2787694%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

C A Nobis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2787694%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

P Fisch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2787694%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

J A Sosman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2787694%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

P M Sondel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2787694%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

publication date

1 January 1989

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2787694%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

5 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2787694%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2787694%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2787694%20AND%20SRC:MED&resulttype=core&format=json

5 October 2019

page(s)

261-269

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2787694%20AND%20SRC:MED&resulttype=core&format=json

The interleukin 2 receptor. Functional consequences of its bimolecular structure

5 October 2019

cites work

1 reference

12 December 2020

Contrasting interleukin 2 binding properties of the alpha (p55) and beta (p70) protein subunits of the human high-affinity interleukin 2 receptor

1 reference

12 December 2020

The human intermediate-affinity interleukin 2 receptor consists of two distinct, partially homologous glycoproteins

1 reference

12 December 2020

Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor

1 reference

12 December 2020

Characteristics of the IL-2 receptor expressed on large granular lymphocytes from patients with abnormally expanded large granular lymphocytes. Implication of a non-Tac IL-2-binding peptide

1 reference

12 December 2020

The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2

1 reference

12 December 2020

Characterization of interleukin 2 (IL-2)-dependent cytotoxic T-cell clones. V. Transfer of resistance to allografts and tumor grafts requires exogenous IL-2.

1 reference

12 December 2020

In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration

1 reference

12 December 2020

Plasma interleukin 2 receptor levels in renal allograft recipients

1 reference

12 December 2020

Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival

1 reference

12 December 2020

Structure-function relationships for the IL-2 receptor system. V. Structure-activity analysis of modified and truncated forms of the Tac receptor protein: site-specific mutagenesis of cysteine residues.

1 reference

12 December 2020

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

12 December 2020

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1 reference

12 December 2020

Potential uses of interleukin 2 in cancer therapy

1 reference

12 December 2020

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

1 reference

12 December 2020

Structure-function relationships for the IL 2-receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein

1 reference

12 December 2020

Status and potential of interleukin-2 for the treatment of neoplastic disease

1 reference

12 December 2020

Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells

1 reference

12 December 2020

Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

1 reference

12 December 2020

On lymphokines, cytokines, and breakthroughs

1 reference

12 December 2020

The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral bloo

1 reference

12 December 2020

Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. A case report and phase I trial

1 reference

12 December 2020

Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

12 December 2020

Establishment of Tac-negative, interleukin-2-dependent cytotoxic cell lines from large granular lymphocytes (LGL) of patients with expanded LGL populations

1 reference

12 December 2020

Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Functional differentiation of human lymphokine-activated killing (LAK) is distinct from expansion and involves dissimilar interleukin 2 receptors

1 reference

12 December 2020

Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients

1 reference

12 December 2020

The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells

1 reference

12 December 2020

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

12 December 2020

Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

1 reference

12 December 2020

Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells

1 reference

12 December 2020

The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities

1 reference

12 December 2020

Interleukin 2 functions through novel interleukin 2 binding molecules in T cells

1 reference

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

12 December 2020

New perspectives in cell adhesion: RGD and integrins

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes

1 reference

12 December 2020

The human interleukin-2 receptor: a molecular and biochemical analysis of structure and function

1 reference

12 December 2020

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity

1 reference

12 December 2020

Nonrestricted cytotoxicity mediated by interleukin 2-expanded leukocytes is inhibited by anti-LFA-1 monoclonal antibodies (MoAb) but potentiated by anti-CD3 MoAb

1 reference

12 December 2020

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

1 reference

12 December 2020

Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells

1 reference

12 December 2020